GENT Fundamental Analysis - GENTIAN DIAGNOSTICS ASA

Fundamental Rating

Taking everything into account, GENT scores 6 out of 10 in our fundamental rating. GENT was compared to 60 industry peers in the Health Care Equipment & Supplies industry. GENT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GENT is growing strongly while it is still valued neutral. This is a good combination!

Quickly go to:

1. Profitability

1.1 Basic Checks

GENT had positive earnings in the past year.

GENT had a positive operating cash flow in the past year.

GENT had negative earnings in 4 of the past 5 years.

In multiple years GENT reported negative operating cash flow during the last 5 years.

1.2 Ratios

GENT's Return On Assets of 18.25% is amongst the best of the industry. GENT outperforms 95.00% of its industry peers.

Looking at the Return On Equity, with a value of 21.37%, GENT belongs to the top of the industry, outperforming 88.33% of the companies in the same industry.

The Return On Invested Capital of GENT (7.59%) is better than 65.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	18.25%
ROE	21.37%
ROIC	7.59%

ROA(3y)0.42%

ROA(5y)-3.57%

ROE(3y)0.25%

ROE(5y)-4.48%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 25.83%, GENT belongs to the best of the industry, outperforming 95.00% of the companies in the same industry.

GENT has a Operating Margin (12.10%) which is comparable to the rest of the industry.

With a Gross Margin value of 54.19%, GENT perfoms like the industry average, outperforming 48.33% of the companies in the same industry.

GENT's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	12.1%
PM (TTM)	25.83%
GM	54.19%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.26%

GM growth 5Y-7.11%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GENT is destroying value.

The number of shares outstanding for GENT remains at a similar level compared to 1 year ago.

Compared to 5 years ago, GENT has about the same amount of shares outstanding.

The debt/assets ratio for GENT has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 15.66 indicates that GENT is not in any danger for bankruptcy at the moment.

GENT's Altman-Z score of 15.66 is amongst the best of the industry. GENT outperforms 100.00% of its industry peers.

The Debt to FCF ratio of GENT is 0.33, which is an excellent value as it means it would take GENT, only 0.33 years of fcf income to pay off all of its debts.

Looking at the Debt to FCF ratio, with a value of 0.33, GENT belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.

A Debt/Equity ratio of 0.02 indicates that GENT is not too dependend on debt financing.

GENT's Debt to Equity ratio of 0.02 is amongst the best of the industry. GENT outperforms 93.33% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	0.33
Altman-Z	15.66

ROIC/WACC0.9

WACC8.45%

2.3 Liquidity

GENT has a Current Ratio of 5.47. This indicates that GENT is financially healthy and has no problem in meeting its short term obligations.

GENT has a better Current ratio (5.47) than 98.33% of its industry peers.

A Quick Ratio of 3.78 indicates that GENT has no problem at all paying its short term obligations.

GENT has a Quick ratio of 3.78. This is amongst the best in the industry. GENT outperforms 95.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.47
Quick Ratio	3.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2103.43% over the past year.

GENT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.68%.

Measured over the past years, GENT shows a very strong growth in Revenue. The Revenue has been growing by 25.96% on average per year.

EPS 1Y (TTM)2103.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-142.41%

Revenue 1Y (TTM)11.68%

Revenue growth 3Y22.3%

Revenue growth 5Y25.96%

Sales Q2Q%13.88%

3.2 Future

GENT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.29% yearly.

GENT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.72% yearly.

EPS Next Y59.41%

EPS Next 2Y62.29%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year31.13%

Revenue Next 2Y31.72%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.07 indicates a rather expensive valuation of GENT.

GENT's Price/Earnings ratio is a bit cheaper when compared to the industry. GENT is cheaper than 80.00% of the companies in the same industry.

GENT is valuated rather cheaply when we compare the Price/Earnings ratio to 27.90, which is the current average of the S&P500 Index.

With a Price/Forward Earnings ratio of 19.90, GENT is valued on the expensive side.

68.33% of the companies in the same industry are more expensive than GENT, based on the Price/Forward Earnings ratio.

GENT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.36, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	20.07
Fwd PE	19.9

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GENT indicates a slightly more expensive valuation: GENT is more expensive than 60.00% of the companies listed in the same industry.

GENT's Price/Free Cash Flow ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	87.97
EV/EBITDA	26.02

4.3 Compensation for Growth

GENT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as GENT's earnings are expected to grow with 62.29% in the coming years.

PEG (NY)0.34

PEG (5Y)N/A

EPS Next 2Y62.29%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a yearly dividend of 0.73%, GENT is not a good candidate for dividend investing.

GENT's Dividend Yield is comparable with the industry average which is at 2.13.

Compared to an average S&P500 Dividend Yield of 2.44, GENT's dividend is way lower than the S&P500 average.

		Industry Rank	Sector Rank
Dividend Yield	0.73%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

DPN/A

EPS Next 2Y62.29%

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENTIAN DIAGNOSTICS ASA

OSL:GENT (10/6/2025, 7:00:00 PM)

-2 (-3.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners25.83%

Inst Owner ChangeN/A

Ins Owners2.59%

Ins Owner ChangeN/A

Market Cap832.68M

Analysts85.71

Price Target68.34 (26.56%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0.73%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-9.55%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	20.07
Fwd PE	19.9
P/S	5.1
P/FCF	87.97
P/OCF	41.86
P/B	4.22
P/tB	5.02
EV/EBITDA	26.02

EPS(TTM)2.69

EY4.98%

EPS(NY)2.71

Fwd EY5.02%

FCF(TTM)0.61

FCFY1.14%

OCF(TTM)1.29

OCFY2.39%

SpS10.6

BVpS12.81

TBVpS10.76

PEG (NY)0.34

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	18.25%
ROE	21.37%
ROCE	9.86%
ROIC	7.59%
ROICexc	12.65%
ROICexgc	17.14%
OM	12.1%
PM (TTM)	25.83%
GM	54.19%
FCFM	5.79%

ROA(3y)0.42%

ROA(5y)-3.57%

ROE(3y)0.25%

ROE(5y)-4.48%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.26%

GM growth 5Y-7.11%

F-Score5

Asset Turnover0.71

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	0.33
Debt/EBITDA	0.11
Cap/Depr	115.57%
Cap/Sales	6.38%
Interest Coverage	250
Cash Conversion	69.08%
Profit Quality	22.43%
Current Ratio	5.47
Quick Ratio	3.78
Altman-Z	15.66

F-Score5

WACC8.45%

ROIC/WACC0.9

Cap/Depr(3y)104.09%

Cap/Depr(5y)116.83%

Cap/Sales(3y)8.32%

Cap/Sales(5y)10.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)2103.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-142.41%

EPS Next Y59.41%

EPS Next 2Y62.29%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)11.68%

Revenue growth 3Y22.3%

Revenue growth 5Y25.96%

Sales Q2Q%13.88%

Revenue Next Year31.13%

Revenue Next 2Y31.72%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y1114.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year215.39%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y257.72%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y8223.43%

OCF growth 3YN/A

OCF growth 5YN/A

GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens